Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Perrigo Company    PRGO

Financials ($)
Sales 2016 5 430 M
EBIT 2016 1 403 M
Net income 2016 -406 M
Debt 2016 5 237 M
Yield 2016 0,76%
Sales 2017 5 595 M
EBIT 2017 1 474 M
Net income 2017 492 M
Debt 2017 4 307 M
Yield 2017 0,83%
P/E ratio 2016 -
P/E ratio 2017 23,05
EV / Sales2016 2,95x
EV / Sales2017 2,69x
Capitalization 10 762 M
More Financials
Perrigo Co. Plc engages in the production of over-the-counter consumer goods and specialty pharmaceutical products.It operates through the following segments: Consumer Healthcare (CHC), Branded Consumer Healthcare (BCH), Prescription Pharmaceuticals, and Specialty Sciences.The CHC segment includes... 
02/23Earnings Release
More about the company
Surperformance© ratings of Perrigo Company
Trading Rating : Investor Rating :
More Ratings
Latest news on PERRIGO COMPANY
09:14a HENDERSON : Sells 21,773 Shares of Perrigo Co. (Prgo)
01/11 S&P 500 MOVERS : Nem, mrk
01/11DJValeant Sheds Assets to Pay Down Debt -- WSJ
01/10DJValeant to Sell Skin-Care Brands to L'Oreal -- 2nd Update
01/10 PERRIGO CO PLC : Results of Operations and Financial Condition, Other Events, Fi..
01/05 PERRIGO : Custopharm Acquires Two ANDA Pharmaceutical Products From Perrigo
2016 U.S. stock market performance in 2016
2016 PERRIGO : Announces FDA Approvals For The Store Brand OTC Equivalents To Nicoret..
2016 STRIDES SHASUN : buys Perrigos US FDA-approved API plant in India
2016 S&P 500 MOVERS : Fcx, lrcx
More news
Sector news : Pharmaceuticals - NEC
01/20 European shares ease ahead of Trump inauguration
01/20 Bristol-Myers shares fall on lung cancer timeline setback
01/19DJRival to EpiPen Allergy Treatment to Return to Market--Update
01/19DJRival to EpiPen Allergy Treatment to Return to Market
01/19 Davos CEOs 'go local' on supply chain in Trump era
More sector news : Pharmaceuticals - NEC
Income Statement Evolution
More Financials
Mean consensus HOLD
Number of Analysts 19
Average target price 104 $
Spread / Average Target 39%
Consensus details
EPS Revisions
More Estimates Revisions
John T. Hendrickson President, Chief Executive Officer & Director
Mary Lauren Brlas Chairman
Judy L. Brown Executive VP, Chief Financial & Accounting Officer
Thomas Farrington Chief Information Officer & Executive VP
Grainne Quinn Chief Medical Officer & Executive Vice President
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON-0.92%310 549
ROCHE HOLDING LTD.0.39%200 499
PFIZER INC.-2.19%192 792
NOVARTIS AG-4.32%185 152
MERCK & CO., INC.6.22%172 404
More Results